Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis

Hepato-Gastroenterology

Volumn 59, Issue 117, 2012, Pages 1609-1613

  Kasuya, Kazuhiko ^a   Tsuchida, Akihiko ^a   Nagakawa, Yuichi ^a   Suzuki, Yoshiaki ^a   Suzuki, Minako ^a   Aoki, Tatsuya ^a   Abe, Yuta ^b   Shimazu, Motohide ^b   Itoi, Takao ^a   Sofuni, Atsushi ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL UNIVERSITY HACHIOJI MEDICAL CENTER   (Japan)

Author keywords

Gemcitabine; Multidrug resistance 1; Pancreatic cancer; Single nucleotide polymorphism

Indexed keywords

ANTIEMETIC AGENT; BREAST CANCER RESISTANCE PROTEIN; DEOXYCYTIDINE PHOSPHATE DEAMINASE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MULTIDRUG RESISTANCE PROTEIN 1; RIBONUCLEOTIDE REDUCTASE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CORRELATION COEFFICIENT; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; INCIDENCE; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS RESECTION; POSTOPERATIVE CARE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ATP-BINDING CASSETTE TRANSPORTERS; CHEMOTHERAPY, ADJUVANT; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; GENETIC TESTING; HETEROZYGOTE; HOMOZYGOTE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PANCREATECTOMY; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84865161329     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11729     Document Type: Article

References (22)

1. Oettle H, Post S, Neuhaus P, et al.: Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized control trial. JAMA 2007; 297:267-277.
2. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I: Genetic analysis of the multidrug transporter. Ann Rev Genet 1995; 29:607-649.
3. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41:1967-1972.
4. Hoffmeyer S, Burk O, Von Richter O, et al.: Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with p-glycoprotein expression and activity in vivo. Proc Nat Acad Sci 2000; 97:3473-3478.
5. Tanabe M, Ieiri I, Nagata N, et al.: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001;297:1137-1143.
6. Kurata Y, Ieiri I, Kimura M, et al.: Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002; 72:209-219.
7. Jiko M, Yano I, Sato E, et al.: Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. Int J Clin Oncol 2007; 12:284-290.
8. Sugimoto Y, Tsukahara S, Ishikawa E, Mitsuhashi J: Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics. Cancer Sci 2005; 96:457-465.
9. De Jong FA, Marsh S, Mathijssen RH, et al.: ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 2004; 10:5889-5894.
10. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W: Cellular Elimination of 2′,2′-Difluorodeoxycytidine 5′-Triphosphate: A mechanism of self potentiation. Cancer Res 1992; 52:533-539.
11. Bergman AM, Pinedo HM, Jongsma AP, et al.: Decreased resistance to gemcitabine (2′,2′-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase. Biochem Pharmacol 1999; 57:397-406.
12. Bergman AM, Eijk PP, Ruiz van Haperen VW, et al.: In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 2005; 65:9510-9516.
13. Bepler G, Zheng Z, Gautam A, et al.: Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer 2005; 47:183-192.
14. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA: An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004; 64:3761-3766.
15. Rosell R, Danenberg KD, Alberola V, et al.: On behalf of the Spanish Lung Cancer Group. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004; 10:1318-1325.
16. Nakahira S, Nakamori S, Tsujie M, et al.: Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 2007; 120:1355-1363.
17. Kwon WS, Rha SY, Choi YH, et al.: Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet Genomics 2006; 16:429-438.
18. Kroep JR, van Moorsel CJA, Veermann G, et al.: Role of deoxycytidinr kinase (dCK), thymidine kinase 2 (TH2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFDC). Adv Exp Med Biol 1998; 431:581-585.
19. Yonemori K, Ueno H, Okusaka T, et al.: Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 2005; 11:2620-2624.
20. Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D: Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer 2010; 16:320-329.
21. Sparreboom A, Gelderblom H, Marsh S, et al.: Diflomotecan Pharmacokinetics in Relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 2004; 76:38-44.
22. Kobayashi D, Ieiri I, Hirota T, et al.: Functional Assessment of ABCG2 (BCRP) Gene Polymorphisms to Protein Expression in Human Placenta. Drug Metab Dispos 2005; 33:94-101.